ATE210124T1 - Diaryl-5-oxygenierte-2-(5h)-furanone als cox-2- inhibitoren - Google Patents
Diaryl-5-oxygenierte-2-(5h)-furanone als cox-2- inhibitorenInfo
- Publication number
- ATE210124T1 ATE210124T1 AT96913412T AT96913412T ATE210124T1 AT E210124 T1 ATE210124 T1 AT E210124T1 AT 96913412 T AT96913412 T AT 96913412T AT 96913412 T AT96913412 T AT 96913412T AT E210124 T1 ATE210124 T1 AT E210124T1
- Authority
- AT
- Austria
- Prior art keywords
- formula
- furanones
- diaryl
- oxygenated
- cox
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Furan Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Handcart (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/443,620 US5691374A (en) | 1995-05-18 | 1995-05-18 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
| PCT/CA1996/000306 WO1996036623A1 (en) | 1995-05-18 | 1996-05-15 | Diaryl-5-oxygenated-2-(5h)-furanones as cox-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE210124T1 true ATE210124T1 (de) | 2001-12-15 |
Family
ID=23761534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96913412T ATE210124T1 (de) | 1995-05-18 | 1996-05-15 | Diaryl-5-oxygenierte-2-(5h)-furanone als cox-2- inhibitoren |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5691374A (de) |
| EP (1) | EP0828724B1 (de) |
| JP (1) | JPH11505534A (de) |
| AT (1) | ATE210124T1 (de) |
| AU (1) | AU707773B2 (de) |
| CA (1) | CA2219129A1 (de) |
| DE (1) | DE69617676T2 (de) |
| DK (1) | DK0828724T3 (de) |
| ES (1) | ES2168471T3 (de) |
| PT (1) | PT828724E (de) |
| WO (1) | WO1996036623A1 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9602877D0 (en) * | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
| US6180651B1 (en) | 1996-04-04 | 2001-01-30 | Bristol-Myers Squibb | Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics |
| US5807873A (en) * | 1996-04-04 | 1998-09-15 | Laboratories Upsa | Diarylmethylidenefuran derivatives and their uses in therapeutics |
| BR9713522A (pt) * | 1996-11-19 | 2000-03-21 | Searle & Co | Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos. |
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
| FR2770131A1 (fr) * | 1997-10-27 | 1999-04-30 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
| FR2771005B1 (fr) * | 1997-11-18 | 2002-06-07 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
| US6025353A (en) * | 1997-11-19 | 2000-02-15 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| JP2002517423A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | シクロオキシゲナーゼ−２の多結合インヒビター |
| US6649645B1 (en) * | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| CO5261541A1 (es) * | 1999-05-14 | 2003-03-31 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de la migrana |
| CO5190664A1 (es) | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
| EP1104759B1 (de) | 1999-12-03 | 2003-10-22 | Pfizer Products Inc. | Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| PT1104760E (pt) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| CA2326970C (en) | 1999-12-03 | 2004-11-23 | Pfizer Products Inc. | Acetylene derivatives as anti-inflammatory/analgesic agents |
| OA12100A (en) | 1999-12-03 | 2006-05-04 | Pfizer Prod Inc | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents. |
| KR100793668B1 (ko) | 1999-12-08 | 2008-01-10 | 파마시아 코포레이션 | 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브 |
| US6465509B2 (en) | 2000-06-30 | 2002-10-15 | Merck Frosst Canada & Co. | Pyrones as inhibitors of cyclooxygenase-2 |
| PE20021017A1 (es) | 2001-04-03 | 2002-11-24 | Pharmacia Corp | Composicion parenteral reconstituible |
| ES2241964T3 (es) | 2001-07-05 | 2005-11-01 | Pfizer Products Inc. | Heterocicloalquilsulfufonilpirazoles como agentes antiinflamatorios/abnalgesicos. |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| GT200200183A (es) | 2001-09-28 | 2003-05-23 | Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol | |
| WO2003037336A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
| AU2003216920A1 (en) | 2002-04-08 | 2003-10-20 | Glaxo Group Limited | (2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives |
| DK3072978T3 (en) | 2002-05-09 | 2018-09-17 | Brigham & Womens Hospital Inc | : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER |
| GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
| EP2384753B1 (de) | 2003-08-29 | 2016-01-06 | The Brigham and Women's Hospital, Inc. | Zellnekrosehemmer |
| WO2005044227A1 (en) * | 2003-11-05 | 2005-05-19 | Glenmark Pharmaceuticals Limited | Topical pharmaceutical compositions |
| US20050100594A1 (en) * | 2003-11-12 | 2005-05-12 | Nilendu Sen | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor |
| ES2381551T3 (es) | 2003-12-05 | 2012-05-29 | The Cleveland Clinic Foundation | Marcadores de riesgo para enfermedad cardiovascular |
| DE602005014359D1 (de) | 2004-06-09 | 2009-06-18 | Sumitomo Chemical Co | Pyridazinverbindung und deren verwendung |
| WO2006041855A2 (en) | 2004-10-04 | 2006-04-20 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
| EP2927693A1 (de) | 2004-10-06 | 2015-10-07 | The Brigham and Women's Hospital | Relevanz erzielter Niveaus von Markern für systemische Entzündung nach Behandlung |
| EP1915157A4 (de) | 2005-08-02 | 2010-09-01 | Nicox Sa | Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren |
| US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| ES2641879T3 (es) | 2006-03-15 | 2017-11-14 | The Brigham And Women's Hospital, Inc. | Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias |
| AU2007243765A1 (en) | 2006-03-29 | 2007-11-08 | Nicox S.A. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
| US20080057590A1 (en) | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
| CA2684308A1 (en) | 2007-04-18 | 2008-10-30 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| GB2460915B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| CN102548969A (zh) | 2009-08-07 | 2012-07-04 | 杜邦公司 | 杀真菌的二苯基取代哒嗪 |
| KR20120139723A (ko) | 2010-02-01 | 2012-12-27 | 더 호스피탈 포 식 칠드런 | 재발협착증의 치료 및 예방을 위한 원격 허혈 처치 |
| CA2795053A1 (en) | 2010-03-31 | 2011-10-06 | The Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
| CN107674071B (zh) | 2012-05-11 | 2021-12-31 | 同步制药公司 | 作为隐花色素调节剂的含有咔唑的磺酰胺类 |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| HUE035883T2 (en) * | 2013-03-26 | 2018-05-28 | Sumitomo Chemical Co | Process for the preparation of a pyridazinone compound |
| TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| EP3292213A1 (de) | 2015-05-04 | 2018-03-14 | Academisch Medisch Centrum | Biomarker für den nachweis von aspirinunempfindlichkeit |
| CN110872263B (zh) * | 2018-09-03 | 2021-09-28 | 郑州大学 | 一种化合物以及制备方法和应用 |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CN111303087B (zh) * | 2020-04-07 | 2021-08-10 | 自然资源部第三海洋研究所 | 呋喃酮类化合物及其制备方法与应用 |
| IL305573A (en) | 2021-03-15 | 2023-10-01 | Saul Yedgar | HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4891061A (de) * | 1972-03-10 | 1973-11-27 | ||
| JPS4891058A (de) * | 1972-03-10 | 1973-11-27 | ||
| JPS50121261A (de) * | 1974-03-12 | 1975-09-23 | ||
| US4302461A (en) * | 1979-08-09 | 1981-11-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory 5-substituted-2,3-diarylthiophenes |
| US4427693A (en) * | 1981-08-05 | 1984-01-24 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines |
| US5207817A (en) * | 1989-09-23 | 1993-05-04 | Bayer Aktiengesellschaft | Herbicidal 5H-furan-2-one derivatives |
| EP0679157B1 (de) * | 1993-01-15 | 1997-11-19 | G.D. Searle & Co. | 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel |
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| SK20396A3 (en) * | 1993-08-19 | 1997-03-05 | Warner Lambert Co | Substituted 2(5h)furanone, 2(5h)thiophenone or 2(5h)pyrrolone derivatives and pharmaceutical compositions on their base |
| US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
-
1995
- 1995-05-18 US US08/443,620 patent/US5691374A/en not_active Expired - Fee Related
-
1996
- 1996-05-15 AU AU56424/96A patent/AU707773B2/en not_active Ceased
- 1996-05-15 PT PT96913412T patent/PT828724E/pt unknown
- 1996-05-15 CA CA002219129A patent/CA2219129A1/en not_active Abandoned
- 1996-05-15 DK DK96913412T patent/DK0828724T3/da active
- 1996-05-15 ES ES96913412T patent/ES2168471T3/es not_active Expired - Lifetime
- 1996-05-15 JP JP8534418A patent/JPH11505534A/ja active Pending
- 1996-05-15 WO PCT/CA1996/000306 patent/WO1996036623A1/en not_active Ceased
- 1996-05-15 DE DE69617676T patent/DE69617676T2/de not_active Expired - Fee Related
- 1996-05-15 EP EP96913412A patent/EP0828724B1/de not_active Expired - Lifetime
- 1996-05-15 AT AT96913412T patent/ATE210124T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0828724T3 (da) | 2002-03-04 |
| WO1996036623A1 (en) | 1996-11-21 |
| AU707773B2 (en) | 1999-07-22 |
| AU5642496A (en) | 1996-11-29 |
| DE69617676T2 (de) | 2002-07-18 |
| EP0828724A1 (de) | 1998-03-18 |
| ES2168471T3 (es) | 2002-06-16 |
| EP0828724B1 (de) | 2001-12-05 |
| PT828724E (pt) | 2002-05-31 |
| DE69617676D1 (de) | 2002-01-17 |
| JPH11505534A (ja) | 1999-05-21 |
| US5691374A (en) | 1997-11-25 |
| CA2219129A1 (en) | 1996-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE210124T1 (de) | Diaryl-5-oxygenierte-2-(5h)-furanone als cox-2- inhibitoren | |
| ATE232856T1 (de) | Diaryl-2(5h)-fuaranone als cox-2-inhibitoren | |
| ATE189218T1 (de) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
| ATE229515T1 (de) | (methylsulfonyl)phenyl-2-(5h)-furanone als cox-2 inhibitoren | |
| DE69616749D1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
| YU59198A (sh) | Supstituisani piridini kao selektivni inhibitori ciklooksigenaze-2 | |
| DE69825603D1 (de) | 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2 | |
| ES2171723T3 (es) | 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2. | |
| DE69825154D1 (de) | Pyridazinone als inhibitoren von cyclooxygenase-2 | |
| CA2211320A1 (en) | 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2 | |
| ATE293602T1 (de) | 2-aminopyridine als inhibitoren von cyclooxygenase-2 | |
| CA2252401A1 (en) | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEIH | Change in the person of patent owner | ||
| REN | Ceased due to non-payment of the annual fee |